Skip to content
2000
image of Exploring the Role of DPF1 in Hepatocellular Carcinoma: Implications for Prognosis and Therapy

Abstract

Background

Hepatocellular carcinoma (HCC) is a life-threatening cancer with rising incidence and mortality rates. Identifying new prognostic biomarkers is crucial for improving HCC management.

Objectives

This study investigates the role of Double PHD Fingers 1 (DPF1) in hepatocellular carcinoma (HCC), exploring its potential as a prognostic indicator and therapeutic target.

Methods

We analyzed DPF1 expression in 374 hepatocellular carcinoma (HCC) tissues and 50 normal tissues from the TCGA-HCC database, as well as in 240 HCC tissues and 202 normal tissues from the ICGC-HCC repository. We examined the correlation between DPF1 expression and clinical parameters, immune cell infiltration, drug response profiles, cancer stem cell (CSC) characteristics, and its diagnostic/prognostic potential using various bioinformatics tools and statistical analyses. Validation was performed using the ICGC and HPA databases, and qRT-PCR was used to confirm DPF1 expression in HCC cell lines.

Results

DPF1 exhibited abnormal expression in HCC and several other malignancies. Elevated DPF1 levels were significantly associated with higher Alpha-fetoprotein (AFP) levels ( = 0.043) and poorer clinical outcomes, including diminished overall survival (OS) ( = 0.002), progression-free survival (PFS) ( = 0.018), and disease-specific survival (DSS) ( = 0.001). DPF1 expression was also linked to immune cell infiltration, immune checkpoint gene expression, drug sensitivity, and CSC characteristics. Notably, DPF1 was significantly overexpressed in HCC tissues and cell lines at both transcriptional and translational levels.

Conclusion

Our study reveals that DPF1 is a novel prognostic biomarker in HCC, with potential implications for immunotherapy and drug resistance. Elevated DPF1 expression is associated with adverse clinical outcomes and may serve as a target for future therapeutic interventions in HCC.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673363347250529114300
2025-06-20
2025-11-04

  • From This Site

    /content/journals/cmc/10.2174/0109298673363347250529114300
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019 69 1 7 34 10.3322/caac.21551 30620402
    [Google Scholar]
  2. Torre L.A. Bray F. Siegel R.L. Ferlay J. Lortet-Tieulent J. Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015 65 2 87 108 10.3322/caac.21262 25651787
    [Google Scholar]
  3. Choi W.T. Kakar S. Immunohistochemistry in the diagnosis of hepatocellular carcinoma. Gastroenterol. Clin. North Am. 2017 46 2 311 325 10.1016/j.gtc.2017.01.006 28506367
    [Google Scholar]
  4. Hartke J. Johnson M. Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin. Diagn. Pathol. 2017 34 2 153 159 10.1053/j.semdp.2016.12.011 28108047
    [Google Scholar]
  5. Kulik L. Heimbach J.K. Zaiem F. Almasri J. Prokop L.J. Wang Z. Murad M.H. Mohammed K. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018 67 1 381 400 10.1002/hep.29485 28859222
    [Google Scholar]
  6. Kobayashi K. Hiramatsu H. Nakamura S. Kobayashi K. Haraguchi T. Iba H. Tumor suppression via inhibition of SWI/SNF complex-dependent NF-κB activation. Sci. Rep. 2017 7 1 11772 10.1038/s41598‑017‑11806‑9 28924147
    [Google Scholar]
  7. Lee S. Suh H.B. Choi S.J. Kang J. Kang J.W. Kwon E.J. Kim H.J. Kim Y.H. Shin K. Identification of prognostic mRNAs in metastatic cutaneous melanoma. Melanoma Res. 2020 30 6 543 547 10.1097/CMR.0000000000000697 33003118
    [Google Scholar]
  8. Toth R. Scherer D. Kelemen L.E. Risch A. Hazra A. Balavarca Y. Issa J.P.J. Moreno V. Eeles R.A. Ogino S. Wu X. Ye Y. Hung R.J. Goode E.L. Ulrich C.M. Genetic variants in epigenetic pathways and risks of multiple cancers in the GAME-ON consortium. Cancer Epidemiol. Biomark. Prev. 2017 26 6 816 825 10.1158/1055‑9965.EPI‑16‑0728 28115406
    [Google Scholar]
  9. Huang Y. Zhou H. Zou J. Wang D. GGT5 is an independent prognostic biomarker in stomach adenocarcinoma. Can. J. Gastroenterol. Hepatol. 2022 2022 1 14 10.1155/2022/9983351 35257007
    [Google Scholar]
  10. Vivian J. Rao A.A. Nothaft F.A. Ketchum C. Armstrong J. Novak A. Pfeil J. Narkizian J. Deran A.D. Musselman-Brown A. Schmidt H. Amstutz P. Craft B. Goldman M. Rosenbloom K. Cline M. O’Connor B. Hanna M. Birger C. Kent W.J. Patterson D.A. Joseph A.D. Zhu J. Zaranek S. Getz G. Haussler D. Paten B. Toil enables reproducible, open source, big biomedical data analyses. Nat. Biotechnol. 2017 35 4 314 316 10.1038/nbt.3772 28398314
    [Google Scholar]
  11. Chen S. Zhang L. Wang K. Huo J. Zhang S. Zhang X. The potential dual role of H2.0-like homeobox in the tumorgenesis and development of colorectal cancer and its prognostic value. Can. J. Gastroenterol. Hepatol. 2023 2023 1 14 10.1155/2023/5521544 37719132
    [Google Scholar]
  12. Cui Z. Liu C. Li H. Wang J. Li G. Analysis and validation of tyrosine metabolism-related prognostic features for liver hepatocellular carcinoma therapy. Curr. Med. Chem. 2024 32 1 160 187 10.2174/0109298673290101240223074545 38415454
    [Google Scholar]
  13. Zhang X. Tang C. Lian J. Jiang Y. A2ML1 inhibits esophageal squamous cell carcinoma progression and serves as a novel prognostic biomarker. Can. J. Gastroenterol. Hepatol. 2023 2023 1 9 10.1155/2023/5557546 37954860
    [Google Scholar]
  14. Liang W. Lu Y. Pan X. Zeng Y. Zheng W. Li Y. Nie Y. Li D. Wang D. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma. Pharm. Genomics Pers. Med. 2022 15 985 998 10.2147/PGPM.S384901 36482943
    [Google Scholar]
  15. Bindea G. Mlecnik B. Tosolini M. Kirilovsky A. Waldner M. Obenauf A.C. Angell H. Fredriksen T. Lafontaine L. Berger A. Bruneval P. Fridman W.H. Becker C. Pagès F. Speicher M.R. Trajanoski Z. Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013 39 4 782 795 10.1016/j.immuni.2013.10.003 24138885
    [Google Scholar]
  16. Yang Y. Gu X. Li Z. Zheng C. Wang Z. Zhou M. Chen Z. Li M. Li D. Xiang J. Whole-exome sequencing of rectal cancer identifies locally recurrent mutations in the Wnt pathway. Aging (Albany NY) 2021 13 19 23262 23283 10.18632/aging.203618 34642262
    [Google Scholar]
  17. Zhao X. Chen Y. Mao Q. Jiang X. Jiang W. Chen J. Xu W. Zhong L. Sun X. Overexpression of YTHDF1 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Biomark. 2018 21 4 859 868 10.3233/CBM‑170791 29439311
    [Google Scholar]
  18. Gu Y. Li X. Bi Y. Zheng Y. Wang J. Li X. Huang Z. Chen L. Huang Y. Huang Y. CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma. Aging 2020 12 1 784 807 10.18632/aging.102656 31927532
    [Google Scholar]
  19. Cao L. Cheng H. Jiang Q. Li H. Wu Z. APEX1 is a novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Aging 2020 12 5 4573 4591 10.18632/aging.102913 32167932
    [Google Scholar]
  20. Chen R. Zhang Y. EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. J. Cell. Mol. Med. 2020 24 20 12107 12118 10.1111/jcmm.15852 32935479
    [Google Scholar]
  21. Guo Y. Shi R. Xu Y. Cho W.C. Yang J. Choi Y.Y. Sun J. Ma Y. Pozharitskaya O. Shikov A. Li H. Li M. Qiu Z. Yang W.M. Duez P. Xu H. Wang X. Bioinformatics-based analysis of fatty acid metabolic reprogramming in hepatocellular carcinoma: Cellular heterogeneity, therapeutic targets, and drug discovery. Acta Materia Med. 2024 3 4 10.15212/AMM‑2024‑0057
    [Google Scholar]
  22. Luo L. Wu X. Fan J. Dong L. Wang M. Zeng Y. Li S. Yang W. Jiang J. Wang K. FBXO7 ubiquitinates PRMT1 to suppress serine synthesis and tumor growth in hepatocellular carcinoma. Nat. Commun. 2024 15 1 4790 10.1038/s41467‑024‑49087‑2 38839752
    [Google Scholar]
  23. Ravindran R. Bacellar I.O.L. Castellanos-Girouard X. Wahba H.M. Zhang Z. Omichinski J.G. Kisley L. Michnick S.W. Peroxisome biogenesis initiated by protein phase separation. Nature 2023 617 7961 608 615 10.1038/s41586‑023‑06044‑1 37165185
    [Google Scholar]
  24. Guo J. Gu H. Yin S. Yang J. Wang Q. Xu W. Wang Y. Zhang S. Liu X. Xian X. Qiu X. Huang J. Hepatocyte-derived Igκ promotes HCC progression by stabilizing electron transfer flavoprotein subunit α to facilitate fatty acid β-oxidation. J. Exp. Clin. Cancer Res. 2024 43 1 280 10.1186/s13046‑024‑03203‑8 39380077
    [Google Scholar]
  25. Fuchs C.D. Simbrunner B. Baumgartner M. Campbell C. Reiberger T. Trauner M. Bile acid metabolism and signalling in liver disease. J. Hepatol. 2025 82 1 134 153 10.1016/j.jhep.2024.09.032 39349254
    [Google Scholar]
  26. Ji F. Zhang J. Liu N. Gu Y. Zhang Y. Huang P. Zhang N. Lin S. Pan R. Meng Z. Feng X.H. Roessler S. Zheng X. Ji J. Blocking hepatocarcinogenesis by a cytochrome P450 family member with female-preferential expression. Gut 2022 71 11 2313 2324 10.1136/gutjnl‑2021‑326050 34996827
    [Google Scholar]
  27. Huang N. Zhang J. Kuang S. Li Z. Zhao H. Wu J. Liu M. Wang L. Role of NCF2 as a potential prognostic factor and immune infiltration indicator in hepatocellular carcinoma. Cancer Med. 2023 12 7 8991 9004 10.1002/cam4.5597 36680322
    [Google Scholar]
  28. Tian Z. Chen Y. Gao B. Natural killer cells in liver disease. Hepatology 2013 57 4 1654 1662 10.1002/hep.26115 23111952
    [Google Scholar]
  29. Xu F. Jin T. Zhu Y. Dai C. Immune checkpoint therapy in liver cancer. J. Exp. Clin. Cancer Res. 2018 37 1 110 10.1186/s13046‑018‑0777‑4 29843754
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673363347250529114300
Loading
Exploring the Role of DPF1 in Hepatocellular Carcinoma: Implications for Prognosis and Therapy
Bentham Science Publishers ; https://doi.org/10.2174/0109298673363347250529114300
/content/journals/cmc/10.2174/0109298673363347250529114300
/content/journals/cmc/10.2174/0109298673363347250529114300
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: drug sensitivity ; prognosis ; Hepatocellular carcinoma ; immune infiltration ; cancer stem cells ; DPF1

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test